What's breaking now, across thousands of outlets.
Another day, another Roche deal. The Swiss pharma is teaming up with Zymeworks, paying $55 million upfront for worldwide rights to a trispecific T cell engager (TCE) that could go head-to-head with Amgen’s Imdelltra. Zymeworks ...
We haven't written up this one. Endpoints News has the full story — the link below goes straight to it.
Quest is the latest in a series of healthcare technology companies that have been hacked in recent months.
What does this mean? Don't miss a story, subscribe here.
RIYADH, Saudi Arabia, Oct. 23, 2026 (GLOBE NEWSWIRE) — King Faisal Specialist Hospital and Research Centre (KFSH) is advancing gene therapy for sickle cell disease through a 2026 clinical trial that…
A first-of-its-kind cancer vaccine is significantly reducing the chances that melanoma patients' tumors come back, according to results of a major study released Thursday by drugmakers Moderna and…
